GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Price-to-Owner-Earnings

CG Oncology (CG Oncology) Price-to-Owner-Earnings : (As of Jun. 07, 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Price-to-Owner-Earnings?

As of today (2024-06-07), CG Oncology's share price is $34.90. CG Oncology does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for CG Oncology's Price-to-Owner-Earnings or its related term are showing as below:


CGON's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.745
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-07), CG Oncology's share price is $34.90. CG Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.71. Therefore, CG Oncology's PE Ratio for today is At Loss.

As of today (2024-06-07), CG Oncology's share price is $34.90. CG Oncology's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.71. Therefore, CG Oncology's PE Ratio without NRI for today is At Loss.


CG Oncology Price-to-Owner-Earnings Historical Data

The historical data trend for CG Oncology's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Price-to-Owner-Earnings Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - -

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial - - - - -

Competitive Comparison of CG Oncology's Price-to-Owner-Earnings

For the Biotechnology subindustry, CG Oncology's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CG Oncology's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where CG Oncology's Price-to-Owner-Earnings falls into.



CG Oncology Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

CG Oncology's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=34.90/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CG Oncology  (NAS:CGON) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


CG Oncology Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of CG Oncology's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


CG Oncology (CG Oncology) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines